Tymlos (abaloparatide; Radius Health/Teijin) is a synthetic peptide analog of human parathyroid hormone-related protein (PTHrP), which binds to the same receptor as parathyroid hormone (PTH).
Endogenous PTHrP plays a central role in the regulation of endochondral bone development, with knockout mice not surviving past birth due to lack of proper bone development. Despite binding to the same receptor (PTHR1), PTHrP and PTH have different functions in vivo.
Although they both act to increase bone mineral density, PTHrP does not induce the subsequent unwanted bone resorption or hypercalcemic responses to the same extent as is seen with PTH. Compared with PTH, Tymlos has been shown to bind with a greater affinity to the conformation of PTHR that positively impacts bone formation.
Key Topics Covered:
List of Figures
Figure 1: Tymlos for osteoporosis - SWOT analysis
Figure 2: Drug assessment summary of Tymlos for osteoporosis
Figure 3: Drug assessment summary of Tymlos for osteoporosis
List of Tables
Table 1: Tymlos drug profile
Table 2: Tymlos Phase III trial data in osteoporosis
Table 3: Tymlos planned Phase III trials in osteoporosis
For more information about this report visit https://www.researchandmarkets.com/research/nf29p3/tymlos?w=4